Expanding transcatheter aortic valve replacement into uncharted indications

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Biomedical Engineering

Background:

• Aortic stenosis (AS) treatment has evolved significantly since 2002.
• Transcatheter aortic valve replacement (TAVR) emerged as a less invasive alternative to surgical aortic valve replacement (SAVR).
• Initial TAVR indications were limited to patients unsuitable for surgery due to high or prohibitive surgical risk.

Purpose of the Study:

• To review the historical development of TAVR.
• To discuss the current applications and evidence supporting TAVR in various surgical risk groups.
• To explore the future directions and potential advancements in TAVR technology and patient selection.

Main Methods:

• This is a review article, synthesizing existing literature and clinical data.
• It examines the evolution of TAVR technology and procedural techniques.
• It analyzes clinical trial outcomes and real-world data on TAVR efficacy and safety.

Main Results:

• TAVR has demonstrated favorable safety and efficacy profiles across multiple studies.
• The use of TAVR has expanded beyond non-surgical candidates to include intermediate-risk patients.
• Evidence is emerging to support TAVR consideration in low-risk surgical patients.

Conclusions:

• TAVR has become a cornerstone therapy for aortic stenosis, offering a viable alternative to SAVR.
• Ongoing research and technological advancements continue to broaden TAVR's applicability.
• The future of TAVR involves further refinement, expanded indications, and personalized patient management.